Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 





















on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 














on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 

















on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 























on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




















on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 


on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 






on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 

(1) International Agency for Research on Cancer. GLOBOCAN 2012: Esitimated Cancer 
Incidence, Mortality and Prevalence Worldwide in 2012. Cancer Fact Sheets: Stomach Cancer. 
2016; Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed July 14, 
2016, 2016. 
(2) Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: 
review and considerations for future directions. Ann Surg 2005 Jan;241(1):27-39. 
(3) Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab 
in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive 
advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, 
randomised controlled trial. Lancet 2010 Aug 28;376(9742):687-697. 
(4) Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in 
combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, 
double-blind, placebo-controlled phase III study. J Clin Oncol 2011 Oct 20;29(30):3968-3976. 
(5) Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, 
oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated 
advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet 
Oncol 2013 May;14(6):481-489. 
(6) Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase 
III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as 
first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 
2006 Nov 1;24(31):4991-4997. 
(7) Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin 
versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III 
trial. Lancet Oncol 2008 Mar;9(3):215-221. 
(8) Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in Combination 
With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive 
Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO- 
013/LOGiC--A Randomized Phase III Trial. J Clin Oncol 2016 Feb 10;34(5):443-451. 
(9) Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. 
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in 


on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010 
Mar 20;28(9):1547-1553. 
(10) Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and 
cisplatin with or without cetuximab for patients with previously untreated advanced gastric 
cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013 May;14(6):490- 
499. 
(11) Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. 
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal 
junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo- 
controlled, phase 3 trial. Lancet 2014 Jan 4;383(9911):31-39. 
(12) Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for 
pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best 
supportive care with best supportive care alone. J Clin Oncol 2012 May 1;30(13):1513-1518. 
(13) Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel 
versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): 
an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014 Jan;15(1):78-86. 
(14) Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus 
paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or 
gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 
trial. The Lancet Oncology 2014;15(11):1224-1235. 
(15) Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 
can function as a negative regulator of T cell activation. Immunity 1994 Aug;1(5):405-413. 
(16) Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical 
and translational research. Cancer Immun 2013;13:5. 
(17) Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved 
survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 Aug 
19;363(8):711-723. 
(18) Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus 
dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 Jun 
30;364(26):2517-2526. 
(19) Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in 
combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small- 


on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin 
Oncol 2012 Jun 10;30(17):2046-2054. 
(20) Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in 
combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell 
lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013 
Jan;24(1):75-83. 
(21) Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab 
(anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis 
and hypophysitis. J Immunother 2007 Nov-Dec;30(8):825-830. 
(22) Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab 
alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: 
results from an open-label, multicenter phase I/II study. Ann Oncol 2013 Jul;24(7):1813-1821. 

(24) Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 
blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin 
Cancer Res 2012 Apr 1;18(7):2039-2047. 
(25) Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, et al. Improved tumor 
immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA 
vaccines in murine melanoma. Cancer Res 2008 Dec 1;68(23):9884-9891. 
(26) Janjigian YY, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. CheckMate-032: 
Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab 
(ipi) in advanced and metastatic (A/M) gastric cancer (GC). ASCO Meeting Abstracts 2016 May 
31;34(15_suppl):4010. 


on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 
 


Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 











































































on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 










































on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 
 
 
 
 
 
 
 

Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 









































































































































on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 
 
 


Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 








on June 30, 2017. © 2017 American Association for Cancer 
Research. 
 
 



on June 30, 2017. © 2017 American Association for Cancer 
Research. 









Ipilimumab 10 mg/kg 
monotherapy (n=57) 

Ipilimumab 10 mg/kg 
monotherapy (n=3)* 

Reasons not treated (n=6) 
• No longer met study criteria (n=2) 
• Withdrew consent (n=4) 
Reasons for not continuing treatment (n=47) 
• Disease progression (n=35) 
• Study drug toxicity (n=4) 
• Completed treatment in induction (n=2) 
• Patient withdrew consent (n=2) 
• Lost to follow-up (n=1) 
• Maximum clinical benefit (n=1) 
• Other (n=1) 
• Patient request to discontinue treatment (n=1) 
Reasons for not continuing treatment (n=54) 
• Disease progression (n=38) 
• Study drug toxicity (n=9) 
• Completed treatment in induction (n=3) 
• Adverse event unrelated to study drug (n=3) 
• Death (n=1) 











Patients at risk 
Ipilimumab 
All best supportive care 











57 
57 
33 
37 
24 
30 
12 
17 
7 
12 
6 
5 
5 
2 
2 
1 
1 
0 
0 
0 
Group 
Ipilimumab 
All best supportive care 

No. of events/no, of patients 
51/57 
40/57 
Median (95% CI) 
2.92 (1.61, 5.16) 
4.90 (3.45, 6.54) 
on June 30, 2017. © 2017 American Association for Cancer 
Research. 












Patients at risk 
Ipilimumab 
All best supportive care 

















57 
57 
53 
49 
48 
45 
42 
41 
35 
35 
33 
30 
27 
24 
24 
19 
17 
14 
12 
12 
9 
8 
6 
5 
4 
3 
3 
2 
0 
1 
0 
0 
Group 
Ipilimumab 
All best supportive care 

No. of events/no, of patients 
36/57 
30/57 
Median (95% CI) 
12.68 (10.51, 18.92) 
12.06 (9.33, NE) 
on June 30, 2017. © 2017 American Association for Cancer 
Research. 



Author Manuscript Published OnlineFirst on June 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0025 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Efficacy of Sequential Ipilimumab Monotherapy vs Best 
Supportive Care For Unresectable Locally Advanced/Metastatic 
Gastric or Gastroesophageal Junction Cancer 
Yung-Jue Bang, Jae Yong Cho, Yeul Hong Kim, et al. 
 



on June 30, 2017. © 2017 American Association for Cancer 
Research. 

Access the most recent version of this article at: 
doi: 

 
Supplementary 
Material 
Access the most recent supplemental material at: 
http://clincancerres.aacrjournals.org/content/suppl/2017/06/27/1078-0432.CCR-17-0025.DC1 
Author 
Manuscript 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been 
edited. 
 
 
 
 
 



Reprints and 
Subscriptions 
To order reprints of this article or to subscribe to the journal, contact the AACR Publications 
Department at 
pubs@aacr.org 
. 

To request permission to re-use all or part of this article, contact the AACR Publications 
Department at 
permissions@aacr.org 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 

